Abstract | BACKGROUND: OBJECTIVES: We evaluated the sensitivity and specificity of serum DNA testing of methylated RUNX3 by the CORD assay in combination with and without CA19-9 for the detection of pancreatic cancer in 55 patients with pancreatic cancer, 12 patients with benign pancreatic disease, and 80 healthy individuals. RESULTS: The CORD assay of methylated RUNX3 had a sensitivity of 50.9% (28/55) and specificity of 93.5% (86/92). Combination of the CORD assay of methylated RUNX3 and CA19-9 resulted in a sensitivity of 85.5% (47/55) and specificity of 93.5% (86/92) for all stages of pancreatic cancer and a sensitivity of 77.8% (7/9) for stage I pancreatic cancer. CONCLUSIONS: ombination of the CORD assay and CA19-9 may provide an alternative screening strategy for detecting early-stage pancreatic cancer.
|
Authors | Yuko Fujimoto, Yutaka Suehiro, Seiji Kaino, Shigeyuki Suenaga, Takanori Tsuyama, Hiroto Matsui, Shingo Higaki, Ikuei Fujii, Chieko Suzuki, Tomomi Hoshida, Toshihiko Matsumoto, Taro Takami, Hiroaki Nagano, Isao Sakaida, Takahiro Yamasaki |
Journal | Oncology
(Oncology)
Vol. 99
Issue 4
Pg. 234-239
( 2021)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 33440396
(Publication Type: Evaluation Study, News)
|
Copyright | © 2021 S. Karger AG, Basel. |
Chemical References |
- Antigens, Tumor-Associated, Carbohydrate
- Biomarkers, Tumor
- Core Binding Factor Alpha 3 Subunit
- Runx3 protein, human
- carbohydrate antigen 199, human
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antigens, Tumor-Associated, Carbohydrate
(blood)
- Biomarkers, Tumor
(blood)
- Core Binding Factor Alpha 3 Subunit
(blood, genetics)
- DNA Methylation
(genetics)
- Early Detection of Cancer
(methods)
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Staging
- Pancreatic Diseases
(blood, diagnosis, pathology)
- Pancreatic Neoplasms
(blood, diagnosis, pathology)
- Polymerase Chain Reaction
(methods)
- Prospective Studies
- Sensitivity and Specificity
|